In this month's column, the authors evaluate the cost effectiveness of oseltamivir and zanamivir, compared with standard care, for the treatment of influenza. Using efficacy data from randomized, placebo-controlled clinical trials, a cost-effectiveness model was constructed. In an influenza-positive patient population, the cost per symptom free day was $16 for zanamivir-treated patients compared with $39 for oseltamivir-treated patients. Considering a hypothetical drug budget of $100,000, 919 additional patients could be treated with zanamivir than with oseltamivir. Treatment with zanamivir would result in a gain of 1,714 symptom-free days and 52 fewer influenza-related complications than if oseltamivir were used.
|Original language||English (US)|
|Number of pages||11|
|State||Published - 2000|
ASJC Scopus subject areas
- Pharmacology (medical)